Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Payables: 2010-2024

Historic Payables for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to $5.5 million.

  • Sunshine Biopharma's Payables rose 47.63% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 40.65%. This contributed to the annual value of $5.5 million for FY2024, which is 114.39% up from last year.
  • Sunshine Biopharma's Payables amounted to $5.5 million in FY2024, which was up 114.39% from $2.6 million recorded in FY2023.
  • Over the past 5 years, Sunshine Biopharma's Payables peaked at $5.5 million during FY2024, and registered a low of $883,324 during FY2020.
  • In the last 3 years, Sunshine Biopharma's Payables had a median value of $2.8 million in 2022 and averaged $3.6 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Payables soared by 119.96% in 2021, and later declined by 7.75% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Payables (Yearly) stood at $883,324 in 2020, then surged by 119.96% to $1.9 million in 2021, then surged by 44.26% to $2.8 million in 2022, then decreased by 7.75% to $2.6 million in 2023, then skyrocketed by 114.39% to $5.5 million in 2024.